stockrow
Friday 6 November 2026
Export ARAY’s income statement to Excel — free account
Accuray Incorporated
ARAY Healthcare Medical Devices
Accuray Incorporated’s revenue for fiscal 2026 (year ended June 2026) was $401.9 million, down 12.3% from fiscal 2025.
- Revenue
- −7.90%
- EPS
- +138.9%
- Free cash flow
- −138.3%
- Total debt
- −25.4%
Quarter to September 2026, against a year earlier
0.11
0.01
−8.33%
Follow ARAY
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.23 | 0.11 | 0.08 | 0.09 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(6.21) | (8.65) | 13.14 | (9.79) | |
P/B ratio |
1.86 | 1.16 | 0.76 | 0.70 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 1.22 | |
EV/Sales |
0.42 | 0.34 | 0.34 | 0.23 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
40.05 | (7.53) | (19.63) | (3.96) | |
EV/FCF |
(66.78) | (5.56) | (10.61) | (3.36) | |
Quick Ratio |
0.52 | 0.50 | 0.57 | 0.00 | |
Current Ratio |
1.47 | 1.42 | 1.50 | 1.56 | |
Net Debt/EBITDA |
(10.65) | (20.39) | 10.74 | (3.19) | |
Debt/Assets |
27.85% | 29.94% | 32.99% | 24.35% | |
Debt/Equity |
2.34 | 3.21 | 3.51 | 1.79 | |
Asset Turnover |
0.94 | 0.92 | 0.88 | 0.93 | |
Operating CF/Net income |
1.16 | 0.47 | (1.25) | (0.38) | |
Capex/Depreciation |
(0.80) | (0.11) | (0.11) | (0.02) | |
Interest Coverage |
(1.50) | (1.08) | 0.64 | (3.09) | |
Research and Development Expense of Revenue |
10.42% | 7.80% | 7.49% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
18.50% | 18.76% | 18.73% | 0.00% | |
Intangible Assets out of Total Assets |
0.13 | 0.13 | 0.13 | 0.06 | |
Share Based Compensation of Revenue |
0.86% | 1.31% | 1.66% | 1.30% | |
Graham Net Nets |
(1.03) | (2.32) | (3.58) | (1.90) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(35.37%) | (94.87%) | (153.85%) | (55.56%) | |
Free Cash Flow Yield |
(2.75%) | (53.43%) | (40.49%) | (72.68%) | |
Revenue per Share |
0.85 | 0.84 | 0.82 | 0.63 | |
Operating CF per Share |
(0.13) | (0.05) | 0.02 | (0.03) | |
Capex per Share |
(0.02) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.16) | (0.05) | 0.02 | (0.03) | |
Cash per Share |
0.35 | 0.31 | 0.34 | 0.00 | |
Shareholders Equity per Share |
0.44 | 0.34 | 0.34 | 0.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.44 | 0.34 | 0.34 | 0.38 | |
Free Cash Flow |
(19.01) | (6.07) | 1.97 | (3.94) | |
Working Capital |
92.95 | 87.37 | 96.37 | 95.94 | |
Capital Expenditures |
(3.02) | (0.47) | (0.46) | (0.12) | |
Net Current Asset Value |
(102.20) | (112.68) | (114.20) | (70.89) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
74.12 | 71.38 | 75.30 | — | |
Average Payables |
48.76 | 49.56 | 37.29 | 37.73 | |
Average Inventory |
149.89 | 151.54 | 144.05 | 150.79 | |
Average Assets |
463.20 | 465.95 | 456.96 | 423.44 | |
Average Common Equity |
50.66 | 45.65 | 61.43 | 57.49 |
Columns are period end dates · fundamentals updated 6 Nov 2026